Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Experimental AMR Payment Program “On Track”

Two Antibiotics To Be Identified For Assessment By Year-End

Executive Summary

Designers of the UK’s experimental antibiotic payment system aim to identify two drugs later this year which will then undergo a novel technology assessment in 2021.

You may also be interested in...



Sweden Urges Pharma To Engage In AMR Initiative

Sweden is testing ‘pull incentives’ in hopes of finding viable reward mechanisms that would ensure adequate access to important antibiotics to meet the Scandinavian country’s domestic internal needs.

AMR Crisis Experts See Hopeful Signs For 2020

2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip. 

US FDA Extends Roche’s Risdiplam Decision Date

 The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.  

Topics

UsernamePublicRestriction

Register

SC141827

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel